Webinar – Evolving Delivery Models for the Next Wave of Advanced Therapies Register your place.
Current Health provides the clinical support infrastructure for moving the delivery of high-cost drugs and therapies like CAR-T and Bispecifics into outpatient, home, and community settings.
Leverage our evidence-based delivery models to create better experiences for providers, patients, and caregivers, and improve financial performance.
Our purpose-built technology, 24/7 expert clinical oversight, and evidence-based escalation protocols provide a safety blanket for high-risk patients.
Delivering advanced therapies like CAR-T and Bispecifics in outpatient models creates better financial alignment. But without continuous, passive monitoring, virtual ICANS assessments, and clear escalation pathways, experiences suffer and scale remains out of reach. Patients and caregivers must take temperature readings manually, often setting middle-of-the-night alarms to adhere to protocols. Providers get 2 a.m. phone calls that may lead to unnecessary visits to unprepared emergency departments.
Current Health reduces the burdens on patients, caregivers, and providers through real-time visibility into safety, clear escalation pathways, and expert nurse oversight.
We’ve partnered with leading cancer centers and pharmaceutical companies to move advanced therapies—including CAR-T and bispecifics—safely into outpatient and home settings.
With therapy-specific protocols, neurotoxicity monitoring, and 24/7 clinical oversight, our model expands access without compromising safety or outcomes.
For years, our clinical research team has been partnering closely with our customers to conduct research on service evaluation and showcase clinical, operational and financial success.
We know what works, and those learnings are baked into our care episodes.
These are some of the research questions we’ve helped answer:
Our solution can be safely relied up on to deliver a virtual immunotherapy program and reduce hospital LOS.
Successful outpatient care depends on multidisciplinary teams, rapid response protocols for managing toxicities like CRS and ICANS, and efficient patient transitions to higher-level care when needed.
A 15-day period is sufficient for capturing nearly all serious adverse events related to FDA-approved CAR-T products, supporting a shorter, efficient monitoring approach.
The success of high-cost therapies depends on real-world delivery beyond the hospital. Outpatient and community models lower total cost of care, strengthen payer negotiations, and drive broader provider uptake.
Current Health provides the infrastructure that ensures therapies like CAR-T, bispecifics, and emerging specialty drugs can be delivered safely, scalably, and credibly across diverse care settings.
Incorporate outpatient/community models into late-stage R&D to accelerate recruitment, while generating robust real-world evidence.
Build payer-ready, outpatient delivery into commercial strategy from day one.
Enable delivery beyond early academic hubs into community networks.
Lower site-of-care costs improve coverage and reimbursement positioning.
Advanced therapies demand high-acuity oversight, but they don’t need to stay confined to the hospital. Our model is built around the unique safety profiles of complex therapies, proven to scale therapies like CAR-T and bispecifics without compromise.
Providers can strengthen patient relationships, expand oncology services, and capture new revenue streams—all while preserving safety and clinical oversight under their own brand.
Designed around the unique safety and monitoring needs of CAR-T, bispecifics, and emerging advanced therapies.
Care remains under your clinicians and brand, strengthening loyalty and referral patterns.
Proven to save bed days and optimize hospital resources, with early adopters transitioning 75%+ of CAR-T to outpatient care while maintaining safety.
Reimbursement-ready, with flexible models that ensure growth works in your favor.
Your clinical and operational infrastructure for better experiences.
Each with predefined patient journeys, alarm parameters, and escalation protocols, ready to deploy from day one.
Our proprietary FDA-cleared continuous wearable and connected devices feed real-time data into a centralized clinical dashboard for timely interventions.
Integrated end-to-end device deployment and reprocessing in fully outsourced or hybrid models.
Put clinical insights where care teams need them—right in your EHR. Turbocharger packages for Epic support fast implementation.
Our RNs and MAs provide continuous oversight, escalating to your care team as needed to maintain safety and staffing efficiency.
Address CRS sooner with our comprehensive solution, which can detect signs of CRS more than 3 hours earlier than standard of care.
Workflows to support detection of early signs of immune effector cell-associated neurotoxicity.
On-demand lab draws and diagnostic testing performed through partners at the patient’s home to ensure timely clinical decision-making without requiring hospital visits.
In the coming weeks, our complex drug and infusion episodes will include daily, integrated ICANS assessments by our Clinical Command Center.
Discover how Sarah Cannon reimagined CAR-T delivery—improving patient experience and easing hospital capacity constraints with a safe, scalable at-home model.
Of CAR-T patients now cared for in outpatient setting
Reduction in LOS for patients requiring inpatient care
Bed days saved in first 100 patients
